Sort by
Refine Your Search
-
Listed
-
Category
-
Program
-
Field
-
cannot be accepted. We aim for a quick selection procedure after the application deadline. The position can start as soon as possible and ultimately by 1 January 2027. Note that international candidates
-
31 December 2028. This means that if the contract starts later than 1 January 2027, it will be shorter than 2 years; if it starts earlier, it may be longer than 2 years (depending on available funding
-
science, data science, research methods, statistics, or a related field, or demonstrate an equivalent level of professional expertise; you have at least three years of relevant experience after your
-
) for 12 months. After a positive evaluation, the position can be extended to 22 months; a working week of 36 - 40 hours and a gross monthly salary between €3.706 and €5.760 (salary scale 10 under
-
plants in the automated phenotyping facilities of the Netherlands Plant Eco-phenotyping Centre (NPEC) . Using high-resolution imaging, you will follow plant growth, physiology and disease development after
-
international candidates that need a visa/work permit for the Netherlands require at least four months processing time after selection and acceptance. Our International Service Desk (ISD) can answer your
-
addresses) of at least two referees. No reference letters are required at the time of application. If you are shortlisted, we will contact your referees, but only after informing you in advance. We aim
-
of the five-year EIC Pathfinder project NOAH; a position available from January 2027, initially for 1 year, extended with 3 years after a positive evaluation; a gross monthly salary, depending
-
, or sustainable cities; the ability to work independently as well as collaboratively in interdisciplinary teams. Our offer We offer: a position 1.0 FTE for 12 months. After a positive evaluation, the
-
group, after which he moved to the biotech industry. With several years of industry experience, he came back to the BioMS group as an assistant professor, leading his own immunopeptidomics group. His